FDA
-
-
-
-
-
-
-
Last Chance for Children is Proud to Announce its Partnership with Generex Biotechnology & NuGenerex Immuno-Oncology to SAFELY and EFFECTIVELY Vaccinate Children and Pregnant Women
-
-
-
-
-
-
-
Generex Subsidiary NuGenerex Immuno-Oncology Announces World Class Scientific Advisory Board Appointments for its COVID-19 Vaccine Development Program
-
-
-
-
-
-
-
Generex Biotechnology Announces That FDA has Accepted the Pre-IND Briefing Package for the Company’s Ii-Key-SARS-CoV-2 Vaccine and Will Provide a Written Response by August 24, 2020
-
-
-
-
-
-
-
Generex Biotechnology Appoints Independent Director S. Gail Eckhardt, MD to the NuGenerex Immuno-Oncology Board of Directors
-
-
-
-
-
-
-
Generex Biotechnology Announces Merger with Public Vehicle for Public Trading of NuGenerex Immuno-Oncology
-
-
-
-
-
-
-
Generex Announces That the Process to Retire 20,375,900 GNBT “Pool Shares” is Complete
-
-
-
-
-
-
-
Generex Biotechnology Reiterates 1:1 Stock Dividend for Clarity in the Market and Provides Details on Capital Structure
-
322,870 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

